Obviousness

The obviousness of US patent 12013326 under 35 U.S.C. § 103 can be assessed by identifying combinations of prior art references that would render the claimed invention apparent to a person having ordinary skill in the art (PHOSITA).

Identified Prior Art and General Knowledge

The patent text for US12013326B2 explicitly references the following as prior art or general knowledge:

1. Steinbach, S et al., (1997) J. Gen. Virol., 78:1453-1462: This reference provides an immunoassay for recombinant adeno-associated viral (rAAV) serotypes. The patent itself highlights that this prior art underscores the need for "a generic assay to characterize recombinant viral preparations regardless of the nucleic acid sequence of the recombinant viral genome or the serotype of the capsid."
2. Berkowitz, S A & Philo J S, (2007) Anal. Biochem., 362:16-37: This publication describes the use of analytical ultracentrifugation (AUC) to characterize adenovirus preparations.

In addition, the patent's "Definitions" section outlines several principles and techniques as generally known in the art prior to the invention's priority date (2015-01-20):

• Analytical Ultracentrifugation (AUC): Described as a long-established and versatile method for evaluating molecular weight and hydrodynamic/thermodynamic properties, including heterogeneity, of proteins and other macromolecules. It explicitly states that "sedimentation velocity yields hydrodynamic properties of particles that may be used to measure characteristics such as size, shape, and concentration."
• Sedimentation Velocity Conditions: Known experimental conditions for studying particles over wide ranges of pH, ionic strength, and temperature. The rate of boundary movement measures the sedimentation coefficient (Svedberg units, S), which depends on molecular weight and shape.
• Lamm Equation: A known mathematical model used to calculate the change in solute concentration boundary over time during ultracentrifugation, accounting for sedimentation and diffusion.
• SEDFIT Algorithm: An established algorithm for analyzing hydrodynamic data, such as sedimentation velocity, by simulating sedimentation boundaries using solutions to the Lamm equation. It is used to derive the differential coefficient distribution value (C(s)).
• C(s) Distribution Analysis: The SEDFIT algorithm generates a C(s) distribution where the area under each peak is proportional to concentration, allowing determination of sedimentation coefficient (Svedberg units) and relative concentration for each component.
• Detection Methods: Absorbance (e.g., at 260 nm for nucleic acids) and interference (e.g., Rayleigh interference) are known optical detection methods for AUC.
• Recombinant Viral Vectors: Adeno-associated virus (AAV), adenovirus, lentivirus, and herpes simplex virus (HSV) are recognized as recombinant viruses used in gene therapy.

Obviousness Analysis of Claims

The core of the claimed invention in US12013326B2 is the application of analytical ultracentrifugation (AUC) for characterizing recombinant viral particles. We will first analyze the broadest independent claim (Claim 1) and then extend the reasoning to the dependent claims.

Claim 1: Method of Characterizing Recombinant Viral Particles

Claim 1: A method of characterizing a preparation of recombinant viral particles comprising the steps of: a) subjecting the preparation to analytical ultracentrifugation under boundary sedimentation velocity conditions wherein the sedimentation of recombinant viral particles is monitored at time intervals; b) plotting the differential sedimentation coefficient distribution value (C(s)) versus the sedimentation coefficient in Svedberg units (S); and c) integrating the area under each peak in the C(s) distribution to determine the relative concentration of each peak, wherein each peak represents a species of recombinant viral particle.

Combination of Prior Art and Motivation:

A person having ordinary skill in the art (PHOSITA) in 2015 would have been motivated to combine the teachings of Berkowitz (2007) with the general knowledge of analytical ultracentrifugation techniques, including C(s) distribution analysis, to arrive at the method of Claim 1.

1. Starting Point: Berkowitz (2007). This reference explicitly teaches the use of AUC for the characterization of adenovirus preparations. Adenovirus is a well-known recombinant viral particle, falling squarely within the scope of "recombinant viral particles" as claimed. This establishes that applying AUC to viral particles for characterization was known prior art.
2. General Applicability of AUC: The patent's own background acknowledges that "AUC analysis has been well characterized over many decades and is highly versatile" and can be used to determine "hydrodynamic properties of particles that may be used to measure characteristics such as size, shape, and concentration." This general knowledge would suggest to a PHOSITA that AUC, already shown effective for adenoviruses, could be applied to other viral particles.
3. Specific Analytical Steps (C(s) plot and integration): The generation of a "differential sedimentation coefficient distribution value (C(s)) versus the sedimentation coefficient in Svedberg units (S)" is explicitly described as a known output of the "SEDFIT algorithm." The SEDFIT algorithm utilizes solutions to the Lamm equation, which itself is known for modeling solute concentration changes during ultracentrifugation. Furthermore, the patent describes that the "area under each peak" in the C(s) distribution is "proportional to concentration," and that "the sedimentation coefficient (in Svedberg units) and the relative concentration (in OD units) are determined for each component in the distribution." These steps are inherent and routine aspects of performing and interpreting sedimentation velocity AUC data using established software like SEDFIT.
4. Motivation for Combination: The patent explicitly articulates a "need" for a "generic assay to characterize recombinant viral preparations regardless of the nucleic acid sequence of the recombinant viral genome or the serotype of the capsid," in contrast to sequence-specific methods like immunoassays (referencing Steinbach, 1997). Faced with this recognized need, and knowing that AUC is a versatile tool for characterizing particles based on their physical properties, a PHOSITA would be motivated to apply AUC, as taught for adenovirus by Berkowitz, to a broader range of recombinant viral particles. The application of standard AUC data analysis methods, such as C(s) plotting and peak integration, would be a routine selection by a PHOSITA to quantitatively characterize the different species present in the viral preparation, as this is precisely what such analysis is designed to achieve.

Therefore, the combination of Berkowitz (2007) (teaching AUC for viral particles) with the widely known principles and standard data analysis techniques of AUC (including C(s) distribution and peak integration as described in references like Schuck (2000) for the SEDFIT algorithm, acknowledged in the patent's background), motivated by the recognized need for generic viral characterization assays, would render Claim 1 obvious.

Dependent Claims (Claims 2-43)

If Claim 1 is deemed obvious, many of its dependent claims would similarly be obvious as they represent either: (a) inherent capabilities or straightforward extensions of the basic AUC characterization, (b) routine optimization choices for AUC parameters, or (c) obvious applications of an analytical tool for monitoring or evaluating processes.

• Claims 2-7 (Assessing genome integrity, detecting/measuring empty/variant capsids): Once AUC is applied to characterize viral particles, the ability to resolve different species (e.g., empty capsids, full capsids, capsids with variant genomes) based on their distinct sedimentation coefficients (S values) is an inherent feature of the technique. Comparing S values to a standard curve (Claim 2), noting additional peaks (Claim 3), and calculating relative concentrations by integrating peak areas (Claims 4-7) are all standard interpretive and quantitative applications of C(s) distribution analysis to characterize heterogeneity in a sample. The patent itself demonstrates these interpretations (e.g., FIGS. 1A, 1B, 2A, 2B, 3A, 3B, 9A, 9C).
• Claims 8 & 10 (Monitoring purification and homogeneity): Using an analytical technique to monitor the progress of a purification process or to assess the homogeneity of a product during manufacturing is a routine and obvious application of any characterization method in a bioprocess setting.
• Claim 9 (Determining heterogeneity): The presence of multiple peaks in a C(s) plot inherently indicates heterogeneity, making this a direct interpretation of the AUC data.
• Claims 11-28 (Specific Method Parameters): These claims specify various operational parameters for AUC, such as detection methods (absorbance, interference), buffer conditions (physiological pH, osmolality), software (SEDFIT), run times, scan numbers, regularization, and S-value ranges. The patent itself frequently states that such parameters are "known in the art" and "within the purview of the skilled artisan to optimize the parameters of AUC for different types of viral particles." Selecting or optimizing these parameters for a particular recombinant viral system would constitute routine experimentation rather than an inventive step.
• Claims 29-39 (Specific Recombinant Viral Particles): These claims specify the type of recombinant viral particle (e.g., AAV, adenovirus, lentivirus, HSV) and even particular serotypes or modified capsids. Given that Berkowitz (2007) taught AUC for adenovirus, and the patent explicitly argues that the method's applicability extends to other viral particles (like AAV, lentivirus, HSV) due to their intermediate sizes, extending the application to these specific viral types and their variants would be an obvious step for a PHOSITA seeking a generic characterization method.
• Claim 40 (Evaluating Production Process): Similar to monitoring purification, using an analytical method to evaluate the quality or outcome of a production process is a standard application of analytical tools in biotechnology.
• Claims 41-43 (Methods for Preparing with Reduced Empty/Variant Capsids): These claims involve a process modification (e.g., culturing cells with a mutated p5 promoter) followed by analyzing the resulting viral particles using the AUC methods described in previous claims. If the AUC analysis (step d) is obvious, then its inclusion as a verification step in a preparation method does not render the entire preparation method non-obvious, especially if the novelty of the preparation method itself (e.g., the specific mutation) is not the focus of this patent's claims. The analytical tool, being obvious, is merely being applied to assess the outcome of another process.

In summary, the broad concept of using AUC for characterizing recombinant viral particles, and the specific steps involved in C(s) distribution analysis (plotting and integration), were either directly taught by prior art (Berkowitz, 2007 for adenovirus) or were well-known analytical techniques within the field of AUC as acknowledged by the patent itself. A PHOSITA, seeking a generic characterization method for gene therapy vectors, would have been motivated to combine these known elements. The dependent claims further detail routine applications, optimizations, or extensions of this obvious core method.